FDA launched stealth drug testing op

Share this article:

Although India's drugmakers may feel as though they are under regulatory attack, a stealth FDA generic drug testing program indicates the agency is taking an across-the-board assessment of non-branded medications that surface in US markets. Bloomberg reports that the $20-million program, which consists of grants to several institutions, started in September “without any public notice” and will run through 2017.

The four-year program is a significant boost to testing which the FDA has generally done only on occasion and when finances allow for it. Bloomberg reports that the acting director of the FDA's generics division put the agency's budget for generics testing at around $2 million to $3 million, when talking about reviews and resources at the Generic Pharmaceutical Association annual meeting. She said new fees have allowed the agency to pursue generics testing in this more robust manner.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.